Remedent Announces Exclusive Agreement With Biotech Medical Aesthetic SAS in Reference to Its Product River 8
February 18 2013 - 12:06PM
Marketwired
Remedent, Inc. (OTCBB: REMI), an international company specializing
in research, development, and manufacturing of oral care and
cosmetic dentistry products, announces its exclusive agreement with
Biotech Medical Aesthetic SAS for distributing its River 8 veneers
worldwide.
River 8 -- the revolutionary, painless, and affordable porcelain
veneer solution for discolored, damaged, stained or misaligned
teeth -- will be produced by Remedent and globally distributed by
Biotech International who are already active in over 40 countries
as market leader in dental and orthopedic surgery implants.
Both partners have agreed upon a renewable 5 years contract with
a first order of 1 million euros (1,35 million USD).
Management Commentary: "We are very
excited about this partnership," comments Mr. Guy De Vreese, CEO of
Remedent. "The River 8 concept and technology is going to radically
transform cosmetic dentistry worldwide, achieving a whitening
result that lasts without bleaching."
Mr. Philippe Veran, CEO of Biotech, adds: "This cooperation fits
perfectly in our vision: we believe cosmetic solutions in general
and veneers in particular will have their undisputed place in every
dental practice of tomorrow."
About Remedent: Remedent Inc. creates
state-of-the-art dental technologies and marketing concepts. Famous
brands are GlamSmile, Remecure, White Boost, Formulation +, and
River 8. Headquartered in Belgium, Remedent Inc. manufactures,
markets and distributes its products and concepts to more than 25
countries worldwide. Remedent Inc. is publicly listed and focuses
on B2B, delivering products to the dental professional, as well as
B2C approaches, helping consumers to obtain their dream smile
through its Smile Consultancy Concept.
Statement under the Private Securities
Litigation Reform Act of 1995 Statements in this press release
that are "forward-looking statements" are based on current
expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and
unknown risks, uncertainties and other unknown factors that could
cause Remedent's actual operating results to be materially
different from any historical results or from any future results
expressed or implied by such forward-looking statements. In
addition to statements that explicitly describe these risks and
uncertainties, readers are urged to consider statements that
contain terms such as "believes," "belief," "expects," "expect,"
"intends," "intend," "anticipate," "anticipates," "plans," "plan,"
"projects," "project," to be uncertain and forward-looking. Actual
results could differ materially because of factors such as
Remedent's ability to achieve the synergies and value creation
contemplated by the proposed transaction. For further information
regarding risks and uncertainties associated with Remedent's
business, please refer to the risk factors described in Remedent's
filings with the Securities and Exchange Commission, including, but
not limited to, its annual report on Form 10-K and quarterly
reports on Form 10-Q.
For more info, please contact: Mr. Luc Maes Marketing
Manager Remedent Zuiderlaan 1-3 box 8, 9000 Gent - Belgium T:
09-2415880 E: info@remedent.com W: www.remedent.com
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Jul 2023 to Jul 2024